• Japanese
  • Korean
  • Chinese
Cover Image

Genitourinary Drugs: Technologies and Global Markets

The total market for genitourinary drugs is projected to increase from $26.5 billion in 2011 to $30.7 billion in 2016 at a compound annual growth rate (CAGR) of 3% for a period of five years, from 2011 to 2016.

The market for hormonal contraceptives was $10.4 billion in 2010, which rose to more than $11 billion in 2011. This segment is further projected to reach $14.5 billion by 2016, a CAGR of 5.7% for a period of five years, 2011 to 2016.

The Benign Prostatic Hypertrophy (BPH) market was valued at $3.9 billion in 2010 and decreased to $3.5 billion in 2011. The market is projected to reach nearly $3.7 billion by 2016, a CAGR of 0.8% for a period of five years, 2011 to 2016.

SUMMARY FIGURE
MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016
($ MILLIONS)*

Source: BCC Research

*Diagnostics are described for various products and
overall disease categories. However, diagnostics are not included
in market figure, as they are outside the scope of this report.

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of the market for genitourinary drugs on a global basis. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends, in order to quantify and qualify the market for drug products to treat various genitourinary diseases in both men and women. Individual drug product-types are forecast on a global basis, as are overall disease segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute the strategy to capture profit from opportunity.

The genitourinary disease drug market presents a significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of genitourinary diseases and the pharmaceutical products for their treatment. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease category. Continued growth is expected in emerging geographies, driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets, specific disease prevalence and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.

The report includes analysis of leading and emerging drug products for each genitourinary disease. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.

Market figures are based on revenues at the manufacturers' level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market

Included in this report are forecasts by product, product category and company from 2009 through 2016. The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each drug subsegment.

Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide. Patent and clinical trial information is reviewed for various drugs. The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

Diagnostics for each disease area and various drugs are described. However, diagnostics are not included in market figures, as they are outside of the scope of this report.

All market share data presented is on a global basis, unless specifically noted.

ANALYST CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early and mid-stage drug development.

Table of Contents

Genitourinary Drugs: Technologies and Global Markets

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, THROUGH 2016
  • Figure Summary: MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016

Chapter - 3: OVERVIEW

  • DISEASES OF THE GENITOURINARY SYSTEM
  • DRUGS GOING OFF-PATENT IN FORECAST PERIOD
  • REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-2016
  • TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011
  • REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT
  • REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA
    • Table 1: GENITOURINARY DISEASE NAMES, GENDER AND DESCRIPTION

Chapter - 4: GENITOURINARY DISEASE CONDITIONS

  • BENIGN PROSTATIC HYPERTROPHY
  • INCONTINENCE AND OVERACTIVE BLADDER
  • ERECTILE DYSFUNCTION
  • INFECTION
  • INFERTILITY
  • HORMONAL CONTRACEPTION
    • Table 7: MAJOR DRUGS APPROVED FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY

Chapter - 5: MARKET ANALYSIS

  • MARKET OVERVIEW
  • MARKET SIZE AND FORECAST
  • CURRENT DRUGS IN THE MARKET
  • PIPELINE FORECAST FOR GENITOURINARY DRUGS
  • MARKET BY MECHANISM OF ACTION AND MODE OF DELIVERY

Chapter - 6: BENIGN PROSTATIC HYPERTROPHY (BPH)

  • OVERVIEW
  • ETIOLOGY OF BENIGN PROSTATIC HYPERTROPHY
  • DIAGNOSIS, TREATMENT AND MANAGEMENT
  • DRUGS BY MECHANISM OF ACTION
  • EPIDEMIOLOGY AND STATISTICS DATA
  • INCIDENCE OF BPH
  • MANAGEMENT OF BPH
  • MECHANISM OF ACTION OF BPH DRUGS
  • MARKET ANALYSIS: REVENUES AND FORECAST
  • BPH DRUG SALES BY MECHANISM OF ACTION
  • MAJOR PLAYERS IN BPH MARKET
  • THE PIPELINE FOR BENIGN PROSTATIC HYPERTROPHY DRUGS IN PRECLINICAL DEVELOPMENT

Chapter - 7: ERECTILE DYSFUNCTION

  • OVERVIEW
  • ETIOLOGY OF ERECTILE DYSFUNCTION
  • DIAGNOSIS, TREATMENT AND MANAGEMENT
  • MECHANISM OF ACTION
  • EPIDEMIOLOGICAL AND STATISTICAL DATA
  • INCIDENCE OF ERECTILE DYSFUNCTION
  • MECHANISM OF ACTION
  • MARKET ANALYSIS AND FORECAST
  • REGIONAL FORECAST FOR ED REVENUES
  • DRUG REVENUES BY MECHANISM OF ACTION
  • MAJOR PLAYERS IN THE ERECTILE DYSFUNCTION MARKET
  • PROFILE OF ERECTILE DYSFUNCTION DRUGS
  • ERECTILE DYSFUNCTION DRUG PIPELINE

Chapter - 8: URINARY INCONTINENCE AND OVERACTIVE BLADDER

  • OVERVIEW
  • DIAGNOSIS, TREATMENT AND MANAGEMENT
  • DRUG REVENUE BY MECHANISM OF ACTION
  • EPIDEMOLOGY AND STATISTICAL DATA
  • MARKET ANALYSIS: SALES AND FORECASTS
  • THE U.S. MARKET FOR INCONTINENCE AND OVERACTIVE BLADDER DRUGS
  • REVENUE FROM IC/OB DRUGS BY COUNTRY OR REGION
  • MAJOR PLAYERS IN THE INCONTINENCE OVERACTIVE BLADDER DRUG SEGMENT
  • PROFILE OF THE APPROVED IC/OB DRUGS
  • COMPANY PIPELINES FOR INCONTINENCE/OVERACTIVE BLADDER DRUGS

Chapter - 9: INFERTILITY

  • INFERTILITY OVERVIEW
  • DIAGNOSIS, TREATMENT AND MANAGEMENT
  • INFERTILITY DRUGS BY MECHANISM OF ACTION
  • EPIDEMIOLOGICAL AND STATISTICAL DATA
  • INCIDENCE OF INFERTILITY
  • MARKET ANALYSIS: SALES AND FORECAST
  • SALES BY MECHANISM OF ACTION
  • MAJOR PLAYERS IN THE INFERTILITY MARKET
  • INFERTILITY DRUG PROFILES
  • PIPELINE FOR INFERTILITY DRUGS

Chapter - 10: HORMONAL CONTRACEPTION

  • OVERVIEW
  • ETIOLOGY OF HORMONAL CONTRACEPTION
  • ORAL CONTRACEPTIVES
  • THE MORNING-AFTER PILL
  • EPIDEMIOLOGY AND STATISTICAL DATA
  • INCIDENCE OF HORMONAL CONTRACEPTIVE USE
  • MARKET ANALYSIS AND FORECAST
  • REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY
  • MAJOR PLAYERS IN HORMONAL CONTRACEPTION DRUGS
  • PIPELINE FOR HORMONAL CONTRACEPTION DRUGS

Chapter - 11: GENITOURINARY INFECTION

  • OVERVIEW
  • MARKET ANALYSIS AND FORECAST
  • MAJOR PLAYERS IN ANTIBIOTICS MARKET
    • Table 86: COMMON BACTERIAL SPECIES IN GENITOURINARY INFECTIONS

Chapter - 12: GLOBAL GENITOURINARY DISEASE DRUG MARKET

  • OVERVIEW
  • GLOBAL REVENUES FROM GENITOURINARY DRUGS
  • GENITOURINARY DRUGS ONLY AVAILABLE IN SPECIFIC COUNTRIES

Chapter - 13: PATENT EXAMPLES FOR GENITOURINARY DRUGS

  • Table 97: U.S. PATENTS FOR GENITOURINARY DRUGS

Chapter - 14: COMPANY PROFILES

  • AGILE THERAPEUTICS
  • ALLERGAN INC.
  • ANTARES PHARMA INC.
  • ASTELLAS PHARMACEUTICALS US INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BOEHRINGER-INGELHEIM GMBH
  • DONG-A PHARMACEUTICAL CO. LTD.
  • ELI LILLY COMPANY
  • ENDO LABORATORIES
  • FERRING PHARMACEUTICALS S.A.
  • GLAXOSMITHKLINE
  • KISSEI PHARMACEUTICAL CO. LTD.
  • MERCK & CO.
  • MERCK SERONO S.A.
  • NOVARTIS INTERNATIONAL AG
  • NYMOX PHARMACEUTICAL CORPORATION
  • PFIZER CORPORATION
  • PREGLEM S.A.
  • RECORDATI S.P.A.
  • ROTTAPHARM SPA
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • VIVUS PHARMACEUTICALS INC.
  • WARNER-CHILCOTT PLC
  • WATSON PHARMACEUTICALS

List of Tables

  • Summary Table: MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, THROUGH 2016
  • Table 1: GENITOURINARY DISEASE NAMES, GENDER AND DESCRIPTION
  • Table 2: GENITOURINARY DRUGS WITH EXPIRING PATENTS, 2010-2016
  • Table 3: FIVE-YEAR PROJECTION FOR REVENUES IN GENITOURINARY DRUG MARKET, THROUGH 2016
  • Table 4: TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011
  • Table 5: REVENUES BY GENITOURINARY SEGMENT, 2011
  • Table 6: REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA, 2011
  • Table 7: MAJOR DRUGS APPROVED FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
  • Table 8: PRESCRIPTION DRUGS THAT HAVE AN ED WARNING
  • Table 9: CURRENT DRUGS FOR ERECTILE DYSFUNCTION TRATMENT
  • Table 10: COMMON BACTERIAL SPECIES IN GENITOURINARY INFECTIONS
  • Table 11: DESIGN OF HORMONAL CONTRACEPTIVE MEDICATIONS
  • Table 12: LONG-TERM CONTRACEPTIVE TREATMENTS
  • Table 13: REVENUE FROM GENITOURINARY DISEASE DRUGS FOR MAJOR COMPANIES, THROUGH 2016
  • Table 14: FIVE-YEAR PROJECTION FOR REVENUE INCREASES IN GENIROURINARY DRUG MARKET, THROUGH 2016
  • Table 15: DRUGS FOR GENITOURINARY DISEASE IN THE PIPELINE WORLDWIDE, 2012
  • Table 16: MECHANISM OF ACTION OF APPROVED DRUGS FOR BPH TREATMENT
  • Table 17: PERCENTAGE OF MALES (OVER FIFTY) WITH BPH AND EXHIBITING SYMPTOMS, 2010
  • Table 18: PROJECTED INCREASE IN MEN WITH SYMPTOMATIC BPH, THROUGH 2016
  • Table 19: MECHANISM OF ACTION OF APPROVED DRUGS FOR BPH TREATMENT
  • Table 20: BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES, THROUGH 2016
  • Table 21: REVENUES FROM THE MAJOR BPH DRUGS, THROUGH 2016
  • Table 22: PROJECTED REVENUES FOR BPH DRUGS BY REGION, THROUGH 2016
  • Table 23: REVENUE FROM BPH DRUGS BY MECHANISM OF ACTION, THROUGH 2016
  • Table 24: MAJOR PLAYERS IN BPH MARKET IN 2011
  • Table 25: PROFILE OF ALPHA-BLOCKER DRUGS
  • Table 26: PROFILE OF 5-ALPHA-REDUCTASE INHIBITOR DRUGS
  • Table 27: PROFILE OF DRUGS WITH ALTERNATIVE MECHANISM OF ACTION
  • Table 28: DRUG FOR BPH PRECLINICAL TRIALS
  • Table 29: BPH DRUGS IN PHASE I CLINICAL TRIALS
  • Table 30: DRUGS IN PHASE II CLINICAL TRIALS FOR BPH TREATMENT
  • Table 31: DRUGS IN PHASE III CLINICAL TRIALS FOR BPH TREATMENT
  • Table 32: BPH DRUGS PENDING APPROVAL FROM U.S. FDA
  • Table 33: FDA APPROVED DRUGS FOR BPH TREATMENT IN 2011
  • Table 34: PROJECTED INCREASE IN ERECTILE DYSFUNCTION, THROUGH 2016
  • Table 35: CURRENT DRUGS FOR ERECTILE DYSFUNCTION TRATMENT
  • Table 36: REVENUES FOR ERECTILE DYSFUNCTION DRUGS, THROUGH 2016
  • Table 37: FORECAST REVENUE INCREASE FROM ERECTILE DYSFUNCTUION DRUGS, THROUGH 2016
  • Table 38: REVENUES AND MARKET SHARE APPROVED ERECTILE DYSFUNCTION DRUGS, 2011 AND 2016
  • Table 39: MAJOR COMPANIES IN THE ERECTILE DYSFUNCTIOMN DRUG MARKET, 2011
  • Table 40: ERECTILE DYSFUNCTION DRUG PROFILES
  • Table 41: DRUGS IN PRECLINICAL DEVELOPMENT
  • Table 42: ERECTILE DYSFUNCTION DRUGS IN PHASE I CLINICAL TRIAL
  • Table 43: ERECTILE DYSFUNCTION DRUGS IN PHASE II CLINICAL TRIALS
  • Table 44: ERECTILE DYSFUNCTION DRIUGS IN PHASE III CLINICAL TRIALS
  • Table 45: ERECTILE DYSFUNCTION DRUGS PENDING FDA APPROVAL
  • Table 46: DRUGS FOR TREATMENT OF INCONTINENCE AND OVERACTIVE BLADDER
  • Table 47: INCIDENCE OF INCONTINENCE AND OVERACTIVE BLADDER
  • Table 48: GLOBAL REVENUES FOR INCONTINENCE AND OVERACTIVE BLADDER DRUGS, THROUGH 2016
  • Table 49: THE U.S. AND EUROPEAN MARKETS FOR INCONTINENCE/OVERACTIVE BLADDER DRUGS, THROUGH 2016
  • Table 50: REVENUES FROM IC/OB DRUGS BY COUNTRY OR REGION, THROUGH 2016
  • Table 51: MAJOR PLAYERS IN THE U.S. INCONTINENCE AND OVERACTIVE BLADDER DRUG MARKET BY MARKET SHARE, 2011
  • Table 52: PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE MARKET
  • Table 53: PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE MARKET
  • Table 54: URINARY INCONTINENACE DRUGS IN PRECLINICAL DEVELOPMENT
  • Table 55: PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS
  • Table 56: PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS
  • Table 57: PIPELINE FOR OVERACTIVE BLADDER DRUGS IN PRECLINICAL DEVELOPMENT
  • Table 58: PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS
  • Table 59: PIPELINE FOR OB DRUGS IN PHASE II CLINICAL TRIALS
  • Table 60: PIPELINE FOR OB DRUGS IN PHASE III TRIALS
  • Table 61: PIPELINE FOR OB DRUGS PENDING FDA APPROVAL
  • Table 62: CAUSES OF INFERTILITY IN WOMEN AND MEN
  • Table 63: INFERTILITY DRUGS BY MECHANISM OF ACTION
  • Table 64: PROJECTED INCIDENCE OF INFERTILITY FOR THE PERIOD, THROUGH 2016
  • Table 65: REVENUES FROM INFERTILITY DRUGS, THROUGH 2016
  • Table 66: MECHANISM OF ACTION OF INFERTILITY DRUGS BY 2011 REVENUE
  • Table 67: MAJOR PLAYERS IN THE INFERTILITY DRUG MARKET
  • Table 68: PROFILES OF COMMON INFERTILITY DRUGS
  • Table 69: PROFILE OF COMMON INFERTILITY DRUGS
  • Table 70: PROFILE OF COMMON INFERTILITY DRUGS
  • Table 71: INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS
  • Table 72: INFERTILITY DRUGS IN PHASE II OR PHASE III CLINICAL TRIALS
  • Table 73: MALE INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS
  • Table 74: DOSING SCHEDULES OF HORMONAL CONTRACEPTIVE MEDICATIONS
  • Table 75: SUMMARYOF LONG-TERM CONTRACEPTIVE TREATMENTS
  • Table 76: USE OF HORMONAL CONTRACEPTIVE METHODS IN SELECTED COUNTRIES
  • Table 77: REVENUES FROM HORMONAL CONTRACEPTION DRUGS, THROUGH 2016
  • Table 78: REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY/REGION, THROUGH 2016
  • Table 79: MAYOR PLAYERS IN THE HORMONAL CONTRACEPTION MARKET
  • Table 80: REVENUES OF MAJOR PLAYERS IN THE HORMONAL CONTRACEPTION MARKET, THROUGH 2016
  • Table 81: PROFILE FOR COMMON DRUGS FOR HORMONAL CONTRACEPTION
  • Table 82: PROFILE FOR COMMON DRUGS FOR HORMONAL CONTRACEPTION
  • Table 83: HC DRUGS IN DEVELOPMENT, PHASE I, II CLINICAL TRIALS
  • Table 84: PIPELINE FOR HC DRUGS IN PHASE III CLINICAL TRIALS
  • Table 85: PIPELINE FOR HC DRUGS PENDING FDA APPROVAL
  • Table 86: COMMON BACTERIAL SPECIES IN GENITOURINARY INFECTIONS
  • Table 87: TYPICAL BACTERIA CAUSING GENITOURINARY INFECTION AND ANTIBIOTICS FOR THEIR TREATMENT
  • Table 88: GENITOURINARY INFECTIONS AND THE ANTIBIOTICS USED FOR TREATMENT
  • Table 89: GLOBAL REVENUES FROM GENITOURINARY DRUGS, THROUGH 2016,
  • Table 90: GLOBAL INCONTENENCE AND OVERACTIVE BLADDER REVENUE FORECAST, THROUGH 2016
  • Table 91: GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES, THROUGH 2016
  • Table 92: GLOBAL REVENUES FROM ERECTILE DYSFUNCTION DRUGS, THROUGH 2016
  • Table 93: PROJECTED GLOBAL REVENUE FROM HORMONAL CONTRACEPTION, THROUGH 2016
  • Table 94: GLOBAL REVENUE FROM INFERTILITY DRUGS, THROUGH 2016
  • Table 95: BPH DRUGS ONLY AVAILABLE IN CHINA
  • Table 96: ERECTILE DYSFUNCTION DRUGS AVAILABLE ONLY IN INDIA
  • Table 97: U.S. PATENTS FOR GENITOURINARY DRUGS
  • Table 98: MERCK & CO, GENITOURINARY DRUG PRODUCTS
  • Table 99: WOMEN'S HEALTH PRODUCTS FROM NOVARTIS
  • Table 100: WARNER CHILCOTT PRODUCTS FOR WOMEN'S HEALTH

List of Figures

  • Summary Figure: MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016
Show More
Pricing